

29 28. The method according to claim *26*, wherein the substance is an aromatase inhibitor.

30 29. The method according to claim *26*, wherein the substance is derived from soya glycine.

31 30. The method according to claim *29*, wherein the substance derived from soya glycine is treated by oxidation.

32 31. The method according to claim *26*, wherein a composition is administered, the composition comprising the substance in an amount of 0.001 to 5 wt.% relative to the total amount of the composition.

33 32. The method according to claim *26*, wherein an effective amount of both an aromatase inhibitor and an anti-estrogen are administered.

34 33. The method use according to claim *26*, further comprising inhibiting the production and/or the effect of dihydrotestosterone.

35 34. The method according to claim *26*, wherein an effective amount of both an aromatase inhibitor and a 5-alpha-reductase inhibitor are administered.

36 35. The method according to claim *26*, wherein the substance has both an inhibitory effect on aromatase and on 5-alpha-reductase.

27
36. The method according to claim 26, wherein the substance is administered locally.

28
37. The method according to claim 26, further comprising improving appearance of a body region.

29
38. The method according to claim 26, further comprising stabilizing, the increasing or restoring collagen in one or more body regions selected from the group consisting of skin, ligaments, fasciae, tendons, cartilages, bones, dentine and the vessel walls of arteries, veins and urinary passageways.

40
39. The method according to claim 26, wherein a pharmaceutical formulation containing the substance is administered, and wherein the pharmaceutical formulation is administered by topical application, by injection, by inhalation or by transdermal therapy.

41
40. The method according to claim 26, further comprising prophylactically treating myocardial infarction or brain infarction.

42
41. The method according to claim 26, further comprising prophylactically or therapeutically treating osteoporosis.

43
42. The method according to claim 26, further comprising prophylactically or therapeutically treating arteriosclerosis.

44
43. The method according to claim 26, further comprising prophylactically or therapeutically treating urinary incontinence.

45 44. The method according to claim *26*, further comprising prophylactically or therapeutically treating for excessive production of glucocorticoids in the body, or accompanying the therapeutic use of glucocorticoids for the decrease of side effects which are associated with glucocorticoids. *27*

46 45. A method for the decrease of hair growth in a mammal, the method comprising administering an effective amount of a substance which inhibits the production and/or the effect of estrogens.

47 46. A method for the cosmetic treatment of wrinkles, strias of the skin or atony of the upper skin, the method comprising administering an effective amount of a substance which inhibits the production and/or the effect of estrogens.

48 47. A method for the amelioration of sun exposure to the skin, the method comprising administering an effective amount of a substance which inhibits the production and/or the effect of estrogens.

49 48. A cosmetic composition for topical application, the composition comprising an inhibitor of the production and/or the effect of estrogens and an inhibitor of the production and/or the effect of dihydrotestosterone.

50 49. The cosmetic composition according to claim *48*, comprising an aromatase inhibitor and a 5-alpha-reductase inhibitor. *49*

Heinrich, et al.
Entry of U.S. National stage of
PCT/EP00/07315
Page 5 of 5

51. 50. The cosmetic composition according to claim 48, wherein the composition comprises a substance which has an inhibitory effect both on the production and/or the effect of estrogens and on the production and/or the effect of dihydrotestosterone.


52. 51. The cosmetic composition according to claim 48, wherein the composition comprises a substance which has an inhibitory effect both on aromatase and on 5-alpha-reductase.--

REMARKS

An early examination and notice of allowance are earnestly solicited. Should the Examiner wish to discuss this application, the undersigned attorney would appreciate the opportunity to do so.

Respectfully submitted,

Date: 13 Feb '02

By: 
George W. Neuner
Registration No. 26,964

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
(617) 439-4444